Production (Stage)
Lipella Pharmaceuticals Inc.
LIPO
$2.99
-$0.10-3.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.18% | -8.60% | 0.71% | -12.44% | -62.02% |
| Total Depreciation and Amortization | 45.83% | 105.88% | 250.00% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -67.67% | -35.73% | -41.39% | -33.25% | 127.57% |
| Change in Net Operating Assets | 253.28% | 1,358.89% | -287.17% | -1,397.11% | -2,282.93% |
| Cash from Operations | -15.25% | -25.41% | -38.95% | -63.00% | -56.60% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -102.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | -900.00% |
| Issuance of Common Stock | 237.17% | 76.33% | -46.97% | -63.50% | -63.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 291.14% | 112.61% | -46.97% | -63.50% | -70.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 210.78% | 39.34% | -146.02% | -171.94% | -153.09% |